STAT January 17, 2025
Joe Grogan

Price controls are a surefire way to crush innovation

President Biden took a groundbreaking step in proposing to cover GLP-1 obesity medications under Medicare and Medicaid in November. But on Friday, his administration announced that Wegovy, one of these drugs, would be subject to price controls. This is a surefire way to crush innovation and discourage new entrants to this important new class of medicines that could help millions of Americans.

GLP-1s, or glucagon-like peptide-1 receptor agonists, are...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Related Articles:
Podcast: The Politics of Alternative Payment Models
Expanding Home- And Community-Based Services For Dually Eligible Adults With Behavioral Health Needs
Self-Interpretation of Imaging by Non-Radiologists Accounts for 43.5 Percent of Medicare Imaging Claims
APG Report Calls for Major Reforms to Medicare, Medicare Advantage
AHIP Medicare, Medicaid, and Duals Conference Wrap Up

Share This Article